Gadgeel SM - Search Results

1

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS^G12C Mutation.

Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Jänne PA, et al. Among authors: gadgeel sm. N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3. N Engl J Med. 2022. PMID: 35658005 Clinical Trial.

2

A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.

Riely GJ, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA. Riely GJ, et al. Lung Cancer. 2007 Feb;55(2):181-5. doi: 10.1016/j.lungcan.2006.10.002. Epub 2006 Nov 7. Lung Cancer. 2007. PMID: 17092603 Clinical Trial.

3

Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.

Heymach JV, Johnson BE, Prager D, Csada E, Roubec J, Pesek M, Spásová I, Belani CP, Bodrogi I, Gadgeel S, Kennedy SJ, Hou J, Herbst RS. Heymach JV, et al. J Clin Oncol. 2007 Sep 20;25(27):4270-7. doi: 10.1200/JCO.2006.10.5122. J Clin Oncol. 2007. PMID: 17878479 Clinical Trial.

4

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.

Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Simon GR, et al. Among authors: gadgeel sm. J Clin Oncol. 2008 Jul 20;26(21):3567-72. doi: 10.1200/JCO.2007.15.2868. J Clin Oncol. 2008. PMID: 18640937 Clinical Trial.

5

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.

Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut MJ, Kalemkerian GP. Schneider BJ, et al. Among authors: gadgeel sm. Invest New Drugs. 2009 Dec;27(6):571-8. doi: 10.1007/s10637-009-9228-6. Epub 2009 Feb 19. Invest New Drugs. 2009. PMID: 19225720 Clinical Trial.

6

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.

Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, Cohen RB, Eisenberg PD, Selaru P, Wilner KD, Gadgeel SM. Haura EB, et al. Among authors: gadgeel sm. Clin Cancer Res. 2010 Apr 15;16(8):2450-7. doi: 10.1158/1078-0432.CCR-09-1920. Epub 2010 Mar 23. Clin Cancer Res. 2010. PMID: 20332327 Clinical Trial.

7

Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.

Schneider BJ, Kalemkerian GP, Ramnath N, Kraut MJ, Wozniak AJ, Worden FP, Ruckdeschel JC, Zhang X, Chen W, Gadgeel SM. Schneider BJ, et al. Among authors: gadgeel sm. Clin Lung Cancer. 2010 Jul 1;11(4):223-7. doi: 10.3816/CLC.2010.n.028. Clin Lung Cancer. 2010. PMID: 20630823 Clinical Trial.

8

Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.

Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP. Schneider BJ, et al. Among authors: gadgeel sm. J Thorac Oncol. 2011 Jun;6(6):1117-20. doi: 10.1097/JTO.0b013e31821529c3. J Thorac Oncol. 2011. PMID: 21512407 Free article. Clinical Trial.

9

XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.

Pietanza MC, Lynch TJ Jr, Lara PN Jr, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R, Mitchell B, Wakelee HA, Miller VA. Pietanza MC, et al. Among authors: gadgeel sm. J Thorac Oncol. 2012 Jan;7(1):219-26. doi: 10.1097/JTO.0b013e31822eebf9. J Thorac Oncol. 2012. PMID: 22011666 Free article. Clinical Trial.

10

Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.

Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM Jr, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA. Pietanza MC, et al. Among authors: gadgeel sm. J Thorac Oncol. 2012 May;7(5):856-65. doi: 10.1097/JTO.0b013e31824c943f. J Thorac Oncol. 2012. PMID: 22722787 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

251 results

Search Page